China Isotope & Radiation Corporation (HKG:1763)

Market Cap	6.22B +57.3%
Revenue (ttm)	8.00B -5.1%
Net Income	364.36M -19.5%
EPS	1.14 -19.5%
Shares Out	319.87M
PE Ratio	17.07
Forward PE	n/a
Dividend	0.36 (1.83%)
Ex-Dividend Date	Jun 23, 2026

Volume	64,000
Open	18.52
Previous Close	19.30
Day's Range	18.49 - 19.59
52-Week Range	14.22 - 25.00
Beta	0.46
Analysts	Strong Buy
Price Target	23.84 (+22.63%)
Earnings Date	Aug 28, 2026

About China Isotope & Radiation

China Isotope & Radiation Corporation engages in the research and development, manufacture, and sale of nuclides, diagnostic, and therapeutic radiopharmaceuticals and radioactive source products for medical and industrial applications in China. The company operates through five segments: Nuclear Medicines; Radioactive Source Products; Irradiation; Nuclear Medical Equipment and Related Services; and Other Businesses. The Nuclear Medicines segment engages in research, development, manufacture, and sale of imaging diagnostic and therapeutic radiop...

• Industry: Medical Devices
• Sector: Healthcare
• Founded: 1983
• Employees: 3,578
• Stock Exchange: Hong Kong Stock Exchange
• Ticker Symbol: 1763

Financial Performance

In 2025, China Isotope & Radiation's revenue was 7.19 billion, a decrease of -5.11% compared to the previous year's 7.57 billion. Earnings were 327.43 million, a decrease of -19.48%.

Financial numbers in CNY

Data Sources: S&P Global Market Intelligence and Financial Modeling Prep

Fundamental and historical data is provided by S&P Global Market Intelligence. Delayed stock pricing data is provided by Financial Modeling Prep.

Last checked:

Jun 19, 2026

Data Sources Report a data error